Industry News

• Fred Hutchinson Cancer Research Center announces new president and director  The Fred Hutchinson Cancer Research Center board of trustees announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director. He is expected to begin as the Center's new leader on Jan. 1, 2011.
  Fred Hutchinson Cancer Research Center July 30, 2010  
• Angiotech Pharmaceuticals announces financial results for the second quarter  Angiotech reported second quarter total revenue was $61.9 million versus $64.5 million in the 2009 second quarter, and a net loss and net loss per share were $14.1 million and $0.17, respectively. As of June 30, 2010, cash and short-term investments were $35.1 million and debt was $539.9 million.
  Angiotech Pharmaceuticals, Inc. July 30, 2010  
• Merck announces second-quarter 2010 financial results  Merck reported second-quarter GAAP EPS was $0.24 versus $0.74 in the 2009 second quarter. Worldwide sales for the second quarter of 2010 were $11.3 billion, and net income for the second quarter was $752 million. Full-Year 2010 Non-GAAP EPS Range of $3.29 to $3.39.
  Merck & Co., Inc. July 30, 2010  
• Bayer increases sales and earnings in the second quarter  The Bayer Group once again achieved gains in sales and earnings in the second quarter of 2010. MaterialScience has left the crisis behind and saw business expand more strongly than expected.
  Bayer July 29, 2010  
• NIH-Funded researchers make progress toward regenerating tissue to replace joints   A team of NIH-funded researchers has successfully regenerated rabbit joints using a cutting edge process to form the joint inside the body. Regenerative in vivo procedures are performed by stimulating previously irreparable organs or tissues to heal themselves.
  National Institutes of Health July 29, 2010  
• Helicos BioSciences announces first evidence of RNA copying mechanisms in human cells  Helicos announced publication demonstrating the detection and quantification of novel small RNA molecules using single-molecule sequencing technology. These data confirm a long-held, unproven hypothesis that mammalian cells are capable of synthesizing RNA by copying RNA molecules directly.
  Helicos BioSciences Corporation July 29, 2010  
• Amgen's second quarter 2010 adjusted earnings per share increased 7 percent to $1.38   Amgen reported adjusted EPS of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 versus $1,311 million for the second quarter of 2009.
  Amgen July 29, 2010  
• Cardiac Science announces second quarter financial results  Cardiac Science reported revenue for the second quarter of 2010 was $36.1 million equal to second quarter 2009 revenue, and a net loss of $18.5 million including a charge of $11.0 million associated with an announced plan to replace AEDs used by certain first responders and medical providers.
  Cardiac Science Corporation July 29, 2010  
• Boston Scientific announces approval of new leads for Precision Plus Spinal Cord System  Boston Scientific announced FDA approval of two spinal cord stimulation leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs.
  Boston Scientific Corporation July 29, 2010  
• UCLA scientists find cell-of-origin for human prostate cancer  UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.
  Jonsson Comprehensive Cancer Center July 29, 2010  

   (next 10 articles)